Shares of Vanda Pharmaceuticals (NASDAQ:VNDA) were flat in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 6.25% year over year to $0.17, which beat the estimate of $0.14.

Revenue of $67,899,000 rose by 9.15% year over year, which missed the estimate of $69,750,000.

Outlook

Vanda Pharmaceuticals Sees FY21 Revs $270M-$300M Vs $282.92M

Details Of The Call

Date: Jul 28, 2021

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/34ig3ksm

Price Action

Company's 52-week high was at $21.86

Company's 52-week low was at $9.00

Price action over last quarter: Up 11.54%

Company Profile